Skip to content

Advertisement

  • Erratum to
  • Open Access

Erratum to: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

  • 1,
  • 2,
  • 3,
  • 4,
  • 4,
  • 1,
  • 4,
  • 1,
  • 4,
  • 3,
  • 4, 5,
  • 1,
  • 4, 5,
  • 3 and
  • 6Email author
Breast Cancer Research20068:403

https://doi.org/10.1186/bcr1390

  • Published:

The original article was published in Breast Cancer Research 2005 7:R617

Following publication of the data presented by von Minckwitz and colleagues [1] it has been brought to our attention that some patients should be scored differently. Stable disease was seen in three of the eighteen patients instead of two of the eighteen patients: one patient with transitional cell carcinoma treated at 4 μg/kg scFv(FRP5)-ETA per day, and two breast cancer patients treated at 4 and 12.5 μg/kg scFv(FRP5)-ETA per day. Disease progression occured in 9 of the eighteen patients evaluated (see corrected Table 2 overleaf). This does not affect the conclusions of our study. In addition we would like to correct the following errors: patient IDs for patients U01 and U02 in the original Table 2 were interchanged. In addition, patient N03 had a grade 3 elevation of gamma-glutamyl transferase, and not grade 2 (see corrected Table 2 overleaf).
Table 2

Study summary

Patient

Dose level (μg/kg)

Course of therapy

Toxicities ≥ grade 1

Dose-limiting toxicity

Neutralizing antibodies

Clinical response

N01

2

According to plan

GGT grade 2

No

No

Progression

U01

2

Stopped on day 10

Cholestasis due to liver metastasisa

No

n.d.

n.d.

U02

2

According to plan

None

No

n.d.

Progression

N03

4

According to plan

GGT grade 2

No

No

Stable disease

N04

4

According to plan

ALT grade 1

No

No

Stable disease

N05

4

According to plan

Hemoglobin grade 3a

No

No

Progression

N06

10

According to plan

ALT grade 2, AST grade 1

No

+

Progression

N07

10

According to plan

ALT/AST grade 1, GGT grade 3

No

No

Progression

U03

10

According to plan

Fever and dyspnoeb

No

++

n.d.c

N13

12.5

According to plan

ALT grade 1, GGT grade 2, AP grade 1

No

No

Progression

N14

12.5

Stopped on day 8

ALT/AST grade 3, GGT grade 2, LDH grade 1

Yes

n.d.

n.d.

N15

12.5

According to plan

ALT grade 2, AST grade 1, AP grade 2

No

+

Progression

N17

12.5

According to plan

ALT/AST grade 2

No

No

Progression

U04

12.5

According to plan

Dyspnoe

No

No

n.d.c

U05

12.5

According to plan

None

No

++

Stable disease

N09

20

According to plan

ALT/AST grade 2

No

+++

Progression

N10

20

Stopped on day 8

ALT grade 4, AST grade 3, GGT grade 2

Yes

n.d.

n.d.

N12

20

Stopped on day 8

ALT grade 3, AST grade 2

Yes

n.d.

n.d.c

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; n.d., not determined.

aCausal relationship with study drug unlikely.

bPatient U03 developed fever and dyspnoe after therapy on day 23, which was resolved with antibiotics; the patient died on day 40, causal relationship with study drug unlikely.

cClinical signs of activity while on therapy including healing of cutaneous lesion (U03, U04), size reduction of lymph node metastasis (U03), and inflammatory response and softening of large tumor mass (N12).

Notes

Authors’ Affiliations

(1)
Department of Gynecology and Obstetrics, University Hospital Frankfurt, Frankfurt am Main, Germany
(2)
Institute for Clinical Pharmacology, University Hospital Frankfurt, Frankfurt am Main, Germany
(3)
G2M Cancer Drugs AG, Frankfurt am Main, Germany
(4)
Medizinische Klinik II, Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt am Main, Germany
(5)
Department of Oncology, University Hospital Zürich, Switzerland
(6)
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Paul-Ehrlich-Straße 42-44, D-60596 Frankfurt am Main, Germany

References

  1. von Minckwitz G, Harder S, Hövelmann S, Jäger E, Al-Batran SE, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, et al: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005, 7: R617-R626. 10.1186/bcr1264.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement